Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Annual Meeting Advocacy Recap

Will Harvey, MD  |  December 2, 2015

Will Harvey, MD

Will Harvey, MD

The 2015 ACR/ARHP Annual Meeting in San Francisco, Nov. 6–10, is now over and was quite an event—our largest ever. The range of scientific and educational opportunities seemed overwhelming—as it always does—and none of us ever has the time to attend every session we want.

Of course, some of you stayed home with your practices and patients. And I want to take a few moments to provide a virtual guided tour of some of the wide range of advocacy sessions that took place at the meeting. Many of these sessions are available on SessionSelect.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On Sunday, Nov. 8, we had our annual Legislative Update session. I started the session with an overview of the problem of rising drug prices and our patients’ inability to afford treatments. The session included an update on the ACR-drafted Patients’ Access to Treatment Act (H.R. 1600), which would eliminate specialty tiers and replace them with a percentage-cost-sharing model. We have 95 co-sponsors for the bill in the House and have had a number of fruitful meetings to advance it over the next year.

We also had a wonderful speaker, Assemblyman David Chiu, who represents much of San Francisco in the California State Assembly. He spoke about a number of issues that need to be addressed in health care. He also provided details about a bill he has introduced in California that would require some transparency around how pharmaceutical manufacturers derive their pricing. He called on organized medicine to get into the debate about the rising cost of medications and told us that our voice was missing in the conversation in terms of how costs affect our ability to treat patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

We ended Sunday’s session with a brief review of other ACR advocacy activities, including our progress on dealing with unfair insurance practices, the shortages of pediatric subspecialists and the strong prospects for increased NIH funding.

Advocacy-2015-Year-in-Review-TRFrom SGR repeal to a safe harbor period for the implementation of ICD-10, ACR/ARHP members have made a huge difference on Capitol Hill and in local constituencies. You can view a handy infographic (right) showing everything our advocates have done in 2015.

Perhaps the most pressing part of the update was in relation to the Medicare Access and CHIP Reauthorization Act (MACRA), which replaced the failed SGR. As I have discussed in prior columns, many parts of this plan still need to be implemented by regulators, who have not always understood to a sufficient degree how their choices affect doctors and patients. We will be spending a large amount of time and resources engaging with regulators to proactively address our concerns. To this end, the ACR has contracted additional regulatory lobbying support.

Page: 1 2 3 | Single Page
Share: 

Filed under:From the CollegeLegislation & AdvocacyProfessional Topics

Related Articles

    Former Senator Tim Hutchinson Urges ACR Members to Advocate for Rheumatology on Local, State and Federal Levels

    January 19, 2017

    WASHINGTON, D.C.—“Regardless of where we are on the political spectrum, we have to get engaged,” said Sen. Tim Hutchinson, senior director, Greenberg Traurig LLP, Washington, D.C., speaking at the 2016 ACR/ARHP Annual Meeting. As a former U.S. senator from Arkansas, Sen. Hutchinson talked about the importance of members in such organizations as the ACR to…

    Advocacy in the Social Media Era

    October 19, 2017

    Advocacy efforts in the medical profession are evolving as technology evolves. The rise of social media, in particular, has brought about great change in the way organizations, such as the ACR, interact with Congress. At the 2017 ACR/ARHP Annual Meeting, Nov. 3–8 in San Diego, former Sen. Tim Hutchinson (R-Ark.) will discuss how to continue…

    Fall 2021’s Awards, Appointments & Announcements in Rheumatology

    October 13, 2021

    Jeffrey Siegel, MD, Assumes New Position as Director for New Office of Drug Evaluation Sciences at the FDA On Feb. 16, Jeffrey Siegel, MD, became the director of the recently created Office of Drug Evaluation Sciences at the U.S. Food & Drug Administration (FDA). The move, he says, “puts together many of the different things…

    ACR Honors U.S. Sen. Susan Collins

    November 13, 2018

    Sen. Susan Collins (R-Maine) is the recipient of the ACR’s 2018 Award for Public Leadership in Rheumatology. Sen. Collins has championed several pieces of legislation that support rheumatologists and rheumatology patients, and she has taken part in multiple efforts to address ongoing concerns in rheumatology. “Sen. Collins has consistently worked both sides of the aisle…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences